Patrick J. Pagano, PhD

Professor

E1247 Thomas E. Starl Biomedical Science Tower
200 Lothop Street
Pittsburgh, PA 15213
Phone: 412-383-6505

Education

BA (Chemistry), Harpur College, SUNY at Binghamton, 1985
MSc (Pharmacology), New York Medical College, 1988
PhD (Pharmacology), New York Medical College, 1991

Links

Patrick J. Pagano, PhD
Link:  Translational Program Project / Vascular Sub-Phenotypes of Lung Disease  http://www.vmi.pitt.edu/tPPG.html 

Dr. Pagano’s research focuses on the modulatory role of the adventitia in vascular function and structure under both physiological and pathophysiological conditions. Dr. Pagano’s laboratory was among the first to identify a non-phagocytic NADPH oxidase in the vascular wall, demonstrating a critical role for essential subunit p67phox in its activity. He subsequently cloned vascular p67phox and illustrated its potent activation at the mRNA and protein level in response to the potent pro-hypertensive hormone angiotensin II. Stemming from these early discoveries, Dr. Pagano was the first to develop specific cell- and tissue-permeant peptidic and adenoviral inhibitor of NADPH oxidase, which is widely considered the most specific NADPH oxidase inhibitor available. These and his other more recently developed inhibitors of novel isoforms of NADPH oxidase are expected to provide a platform for the development of new therapies aimed at treating hypertension and other cardiovascular diseases. Moreover, Dr. Pagano is broadly recognized for his pioneering work examining the role of adventitia-derived reactive oxygen species (ROS) and, in particular, superoxide anion and hydrogen peroxide in the modulation of vascular tone, inflammation, and remodeling.

http://www.vmi.pitt.edu/pagano.html

http://paganolab.pitt.edu/




 

Journal Articles

Ardanaz N, XP Yang, ME Cifuentes, MJ Haurani, KW Jackson, T Liao and PJ Pagano.  Lack of glutathione peroxidase 1 accelerates cardiac-specific hypertrophy and dysfunction in angiotensin II hypertension.  Hypertension 55:116-123, 2010.
Haurani MJ, ME Cifuentes, AD Shepard and PJ Pagano.  Nox4 oxidase overexpression specifically decreases endogenous Nox4 mRNA and inhibits angiotensin II-induced adventitial myofibroblast migration.  Hypertension 52:143-149, 2008.
Dourron, H.M., G.M. Jacobson, J.L. Park, J. Liu, D.J. Reddy, M.L. Scheel, and P.J. Pagano. Perivascular gene transfer of an NADPH oxidase inhibitor suppresses angioplasty-induced neointimal proliferation of rat carotid artery. Am. J. Physiol. Heart Circ. Physiol. 288: H946-H953, 2005.
Liu, J., A. Ormsby, N. Oja-Tebbe, and P.J. Pagano. Gene transfer of NAD(P)H oxidase inhibitor to the vascular adventitia attenuates medial smooth muscle hypertrophy. Circ. Res. 95: 587-594, 2004.
Rey, F.E., X.-C. Li, O.A. Carretero, J.L. Garvin, and P.J. Pagano. Perivascular superoxide anion contributes to impairment of endothelium-dependent relaxation. Role of gp91phox . Circulation 106:2497-2502, 2002.
Rey, F.E., M.E. Cifuentes, A. Kiarash, M.T. Quinn, and P.J. Pagano. A novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O2 and systolic blood pressure in mice. Circ. Res. 89: 408-414, 2001.
Pagano PJ, SL Chanock, DA Siwik, WS Colucci and JK Clark.  Angiotensin  II induces p67phox mRNA expression and NADPH oxidase superoxide generation in rabbit aortic adventitial fibroblasts.  Hypertension 32:331-337, 1998.
Pagano, P.J., J.K. Clark, M.E. Cifuentes-Pagano, S.M. Clark, G.M. Callis, and M.T. Quinn. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc. Natl. Acad. Sci. USA 94: 14483-14488, 1997.

Sponsored Research

Progressive degenerative role of Nox and thrombospondin-1 in the aging - 4/1/2019 - 2/28/2023
NIH - R01HL142248
Progressive degenerative role of Nox and thrombospondin-1 in the aging vasculature - 7/1/2018 - 6/30/2021
AHA - 18TPA34170069
Vascular Subphenotypes of Lung Disease (Proj. 2) - 8/1/2016 - 4/30/2021
NIH - P01HL103455
Hemolysis-induced platelet mtROS drives TSP1 release to accelerate PH pathogenesis - 4/5/2017 - 1/31/2021
NIH - R01HL133003
Predoctoral Training in Pharmacological Sciences - 7/1/2015 - 6/30/2020
NIH - T32GM08424
Integration of Career Coaching for Trainees and Coaching Skills Development for Mentors - 7/1/2018 - 6/30/2019
NIH - T32GM008424